CanaQuest Medical Corp. has filed a Provisional Cannabidiol/Omega-3 Patent, trade named Mentanine®, which was developed as a result of its sponsored research program at Western University, based in London, Ontario, Canada. The application of CBD alone has little effect/impact on the ability of the Central Nervous System “CNS” to help with mental health issues. The company newly developed formula will be a “life changer” for many. The scientifically developed formula went through pre-clinical studies at Western University. Results from these pre-clinical trials, addressing anxiety, depression, PTSD, and schizophrenia have been statistically significant. These results also reduced inflammation, which has beneficial implications for pain. The application of this formulation can decrease opioid addiction effects and schizophrenia-related symptoms. Mentanine® a scientifically developed and formulated medical product is tasteless and can be produced as a water-soluble liquid and powder, with significantly improved bioavailability. The liquid version of this product was produced and successfully tested for quality and safety by third party laboratories in the USA and Canada. Pre-clinical trials: Indicated more than 10 times the efficacy as compared to CBD molecules alone; Reduced Anxiety, Depression, PTSD and Addictive effects; Demonstrated significant reduction of inflammation, which can be beneficial for pain management. As a result, this formulation can be administrated with significantly smaller doses of medical CBD, therefore, reducing or even eliminating the negative side effects caused by high consumption of other competing CBD oils available on July 14, 2020.